In the 1980s, 50% of all hemophilia patients developed AIDs due to poor manufacturing standards.

​

At the launch of its hemophilia agent, HEMLIBRA, Genentech saw how important it was to help the community feel safe when taking their medication. 

​

Despite remaining unproduced, Match-Cut was a true passion project, an ode to all workers involved in the manufacturing process, presenting match-cuts from developmental scientists, to production leads, to the delivery personnel at the end of the road.